Today’s AI Top Pick: ALNY

9/17/2026 · Reliable Bullish screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

The desk streams live daily· see the schedule →

Measured daily model accuracy · ALNY84%465 resolved forecasts · 45d window · verify →

Today's pick · Reliable BullishALNYBUY NOW8.6 / 109/17/2026

ALNY is the cleanest fundamentals-plus-setup combo in this pool. It carries a top-tier fundamental_score of 8 with bullish_prob 1.0, and the numbers back it up: PEG 0.32, ROE 100.7%, salesYoY +95.14%, epsNextY +50.99%, gross margin 79.65%, and analyst recom 1.62 with 56.4% target upside. This is not a speculative story — it's a scaled ($32B cap) biotech with real RNAi commercial momentum that has been beaten down -39.81% YTD and -48.11% over the year, which is exactly the kind of washout-into-quality that this screen is designed to catch. The tape confirms without asking you to chase. On the 4h, price is at just 0.37% of its 21-bar range with a -27.65% drawdown, and the model is calling for +72.41% short / +66.6% mid / +70.07% long — an unusually large forecast magnitude that suggests the algo sees mean-reversion from deeply oversold. The 1d timeframe agrees more moderately (pos 26.4%, fc_mid +53.92%, fc_long +31.66%). Only the 1wk is soft (fc_short -1.55%, fc_mid +1.73%), which is fine — that's the timeframe still absorbing the -19.17% recent weekly move. RSI 44.75 leaves plenty of room to run before overbought. Recent headlines are neutral-to-constructive: coverage around RNAi repricing and oligonucleotide market optimism, no guidance cut, no legal overhang, no dilution chatter. Compare to WAY (already ripped 7% on a sale rumor, 100% of range — pure chase), FUTU (4h at 99.88% of range, weekly forecasts negative), or TIGR (4h at 97.14% — great forecast but you're paying the top tick). ALNY gives you the strongest forecast magnitudes AND the best entry location AND the best fundamentals in one name. Entering today makes sense because you're buying near the 4h low with the daily forecast already turning up and multi-timeframe alignment on the constructive side. Waiting risks missing the mean-reversion snapback that the 4h forecast is screaming for.

Entry zone

$235-$243 (current $239.36, scale in on any dip toward 4h low)

Stop loss

$218 (below the recent 4h low; roughly -9% risk, invalidates the mean-reversion thesis)

First target

$268-$275 (retrace 50% of the recent -27% 4h drawdown, ~+12-15%)

Longer target

$310-$325 (aligns with the 1d fc_long of +31.66% and analyst target upside of 56%)

Risks

1wk timeframe forecasts still slightly negative (fc_short -1.55%) — weekly trend has not confirmed the bounce yet
Debt/Eq 2.21 is elevated for biotech and could compress multiples if rates back up
Stock is -48.11% over the past year and -39.81% YTD — real institutional distribution has occurred; downtrend can resume
Pipeline/clinical trial risk is idiosyncratic to biotech and not captured in the forecast model
Fwd PE 23.75 is not cheap in absolute terms if the 95% sales growth decelerates

Honorable mentions

CRKFundamental_score 7.5, bullish_prob 1, and a real catalyst: $1.65B SOCAR letter of intent + $450M Jerry Jones drilling JV materially improve the deleveraging story. 4h pos 8.99% with fc_short/mid/long of +64.86/+68.07/+76.36% is a monster setup. Only knock is recom 2.88 (weakest analyst view in the pool) and energy sector cyclicality.

TIGRCheapest name here (fwdPe 5.99, PE 7.92) with bullish_prob 1, near_term 0.8, and forecast magnitudes of +81.9/+84.4/+92.8% on the 4h. Held back only because 4h pos is 97.14% — you're buying the top of that specific timeframe's range, so a small pullback would be a cleaner entry.

Full ranking (15)

#	Symbol	Verdict	Score	Read
1	ALNY	BUY NOW	8.6	Fund_score 8, prob 1.0, 4h pos 0.37% with +72% forecast — best fundamentals-plus-entry combo in the pool.
2	CRK	BUY NOW	8.1	SOCAR/Jones deals + prob 1 + 4h pos 8.99% and fc_long +76% — huge asymmetric setup on a deleveraging catalyst.
3	TIGR	BUY PULLBACK	7.7	FwdPe 5.99, prob 1, fc_long +92.8% — but 4h at 97% of range, wait for a dip to $4.50.
4	ETOR	BUY NOW	7.4	Fund_score 8, 1d pos 0%, fc_long +39.3% — oversold quality fintech with 71% analyst upside.
5	FIGR	BUY PULLBACK	7.2	Fund_score 8 and positive AI-agent catalyst, but 4h pos 80% while 1d pos 5.79% — mixed tf alignment.
6	MIR	BUY NOW	7.0	Prob 1, near_term 1, CFO bought 20k shares, Jefferies initiated Buy, 4h pos 4.82% with fc +46-58%.
7	FUTU	BUY PULLBACK	6.7	Great fundamentals but 4h at 99.88% of range and 1wk forecasts negative — don't chase here.
8	VERX	BUY PULLBACK	6.3	Prob 1, near_term 1, fc_long +53.8% on 1d — but PE 585 and profit margin 0.45% are red flags.
9	CLBT	BUY PULLBACK	6.2	Prob 1, recom 1.0 (unanimous strong buy), redomicile to US positive — but 1wk forecasts still negative.
10	DOX	BUY PULLBACK	6.0	Prob 1, cheap (fwdPe 7.66), 1wk fc_long +28.98% — but 4h pos 85% is elevated, wait for pullback.
11	ARI	WAIT	5.6	13% yield thesis and 4h fc +65-72% is enticing, but 1wk forecasts negative and salesYoY -63%.
12	CCC	WAIT	5.3	1wk fc_long +53% but 1d pos 0% with fc_short/mid only +0.5% — near-term drift, no catalyst.
13	BR	WAIT	5.1	Solid company but 4h pos 91%, near_term_bullish 0, and forecasts flat-to-weak on higher tfs.
14	WAY	AVOID	4.8	At 100% of weekly range on sale rumor, bullish_prob 0, fc_short/mid negative — pure chase, no edge.
15	SE	AVOID	4.5	bullish_prob 0.4, near_term 0.2, 4h forecasts near zero — screen pass but tape says wait.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord